Operator
Welcome to INmune Bio’s Second Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference call is being recorded. A transcript will be available approximately 24 hours after the call.
Before we begin, please note that except for statements of historical fact, statements made by management and responses to questions may constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
There are a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied. We encourage you to review the forward-looking statements disclaimer in today’s earnings release and the risk factors described in the company’s filings with the SEC, including its most recent quarterly report. Forward-looking statements speak only as of the date they are made and except as required by law, INmune Bio undertakes no obligation to update them.
It is now my pleasure to turn the call over to INmune Bio’s Chief Executive Officer, David Moss.
David Moss
President, CEO, Treasurer, Secretary & Director
Thank you for joining INmune Bio’s second quarter conference call. The second quarter and the weeks that followed were defined by execution across both of our late-stage platforms. I will begin with the investor perspective on the progress we have made. I will then turn the call over to Dr. Mark Lowdell, our Chief Scientific Officer and the inventor of CORDStrom to discuss Ebstrocel and